What’s next for CRISPR & gene therapy, plus a China Summit Preview
Emerging Company Spotlight: Elpiscience and Rectify
By Jeff Cranmer, Executive Editor
October 26, 2021 1:18 AM UTC
BioCentury & Getty Images
On the BioCentury This Week podcast, BioCentury’s editors dig into the latest trends in CRISPR and gene therapy, both in the lab and at biopharmas.
Senior Editors Karen Tkach Tuzman and Lauren Martz discuss advances in gene editing machinery that have come via engineering or through the discovery of new natural nucleases with advantageous properties, and takeaways from BioCentury’s analysis of what 51 gene therapy companies founded in the last five years are working on. Martz also previews BioCentury’s look at gene therapy deals in the past two years.
Then, BioCentury Executive Director Josh Berlin and Editor in Chief Simone Fishburn preview the BioCentury-BayHelix China Healthcare Summit, which will be a hybrid event held in Shanghai and online Nov. 16-19. Among multiple panels, events and 1-on-1 meetings, attendees will receive a report on the globalization of China biotech prepared by insights partner McKinsey & Co. as well as Fishburn’s deep dive analysis into what the next class of biopharma bellwethers from China will look like.
Executive Editor Jeff Cranmer wraps the episode by detailing BioCentury’s two most recent Emerging Company Profiles: Shanghai-based Elpiscience Biopharma Inc., which is led by Darren Ji and developing a broad immuno-oncology pipeline headlined by a CD39 franchise, and Rectify Pharmaceuticals Inc., a Cambridge, Mass. ABC transporter company that debuted this month with a $100 million series co-led by Atlas Venture, Omega Funds, Forbion and Longwood Fund.
